Chewy Met Its Numbers and Fell 11%: A Single-Digit Grower Still Priced Like a Hypergrowth Stock

Chewy just gave investors a report that reads, on paper, like a win. For the quarter ended July 2026, net sales rose 7.3% to $3.33 billion, a hair above the $3.32 billion consensus. Adjusted earnings of $0.36 per share met estimates. Management even raised its full-year revenue and margin guidance. So why did the stock get hammered — down about 11% in the session to roughly $20.75, and down roughly 37% year to date?

The market wasn't punishing the quarter. It was repricing the company the quarter revealed.

A mature P&L that keeps getting better

Strip the headline away and the operational story is hard to fault. Adjusted EBITDA came in at $226.7 million, a 6.8% margin that expanded about 90 basis points year over year. Free cash flow over the trailing twelve months came to $568 million, up 22.7%. Active customers grew 3.8% to 21.7 million, and Autoship — Chewy's subscription engine — accounted for 84.6% of revenue.

That Autoship number is the heart of the durability argument. When nearly 85% of sales recur on a schedule, revenue is less a bet on impulse buying and more a steady cash machine. Add a lightly leveraged balance sheet, and you have what looks like the safe, cash-generative sleeve of a barbell: a business that throws off real free cash flow, at a 72% return on equity, with no dividend to prop it up by borrowing.

None of that is in dispute. The dispute is what the market should pay for it.

The catch is the growth rate

Here is the number the headline buries. That 7.3% top-line increase includes the SmartPak and Modern Animal acquisitions. Organically, sales grew 5.7%. Chewy is no longer a hypergrowth company; it is a single-digit grower with a high-quality, recurring base.

Management was blunt about the environment. On the call, the pet market was described as "broadly stabilized" — an improvement from the earlier weakness — but still weak, with no meaningful recovery in consumer demand assumed for the rest of the year. Customers are prioritizing core food and medication while discretionary treats lag. Chewy is taking share, outperforming the broader pet category by an estimated two to three times, but it is doing so inside a soft category.

That is also why the "in-line" EPS deserves a closer look. The margin upside that drove the EBITDA beat was, by management's own account, partly timing-related and discrete — tariff refunds, rebates, and gift card breakage — rather than pure operating leverage. And because the market had hoped for an EPS beat and got a match, the reaction was punishing.

The factor read: strong quality, weak timing, full price

Through a systematic, sector-relative lens, Chewy's report card is genuinely split. Profitability and safety are A-grade: roughly 30% gross margin, 72% return on equity, strong free cash flow, and a nearly unlevered sheet. Growth is C-grade at best — mid-single-digit organic, decelerating quarter over quarter. Momentum is a D: the stock sits below both its 50- and 200-day moving averages, and the rolling one-year return is about minus 40%. Valuation, in our book, is the loaded question.

Chewy trades near 30 times trailing EBITDA and above 30 times forward earnings — a multiple that belongs to a company growing its top line in the teens or twenties. For a business growing 5.7% organically, that is the market still charging a hypergrowth price. The falling share price is the market slowly making that multiple smaller, quarter by quarter.

The aggregate signal from AInvest still labels Chewy a Buy, and on pure business quality that is defensible. But a Buy label tells you the asset is good, not that the entry price is right. The five-factor stack passes quality and safety and fails growth and momentum, which is precisely the divergence that produces slow, painful re-ratings.

What this means for a portfolio

Chewy's role in a portfolio is the durable-cash-flow one, not the growth one. If you own it, you're not buying a story about the pet-population boom or a stock doubling on AI hype — you're buying a high-quality, recurring-revenue operator that converts its sales into cash and holds a safe balance sheet. That is a legitimate sleeve, and in a barbell it pairs naturally with steady cash payers against more speculative growth.

The problem is the entry price relative to that slower reality. At this multiple, the investment case depends on one of two things happening: the pet market recovering enough to lift organic growth back toward double digits, or the multiple resetting further to match single-digit growth. The current price already reflects a lot of the bad news — the stock has shed more than a third of its value this year and trades near the bottom of its range. But with management guiding to a permanently softer consumer, the burden is still on either a recovery or a cheaper price to make the math work. Until one of those moves, the quality and the price are fighting each other, and the share price is the scoreboard.